 AUSTIN, Texas, Oct. 26, 2020 PRNewswire -- Aeglea BioTherapeutics, Inc. NASDAQ: AGLE, a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced the U.S. Food and Drug... 